<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>Tirzepatide on Rheumatology Digest</title><link>https://rheumatologydigest.org/tags/tirzepatide/</link><description>Recent content in Tirzepatide on Rheumatology Digest</description><generator>Hugo</generator><language>en-us</language><lastBuildDate>Fri, 16 Oct 2026 05:00:00 +0530</lastBuildDate><atom:link href="https://rheumatologydigest.org/tags/tirzepatide/index.xml" rel="self" type="application/rss+xml"/><item><title>Ixekizumab Plus Tirzepatide in PsA: TOGETHER-PsA</title><link>https://rheumatologydigest.org/posts/ixekizumab-tirzepatide-together-psa/</link><pubDate>Fri, 16 Oct 2026 05:00:00 +0530</pubDate><guid>https://rheumatologydigest.org/posts/ixekizumab-tirzepatide-together-psa/</guid><description>Adding tirzepatide to ixekizumab beat ixekizumab alone on ACR50 and weight loss — but the trial was open-label, and the primary endpoint was weight-driven.</description></item></channel></rss>